Bromantane (Ladasten)
Adamantane Actoprotector | Dopamine Synthesis Enhancer
On this page
What is Bromantane (Ladasten)?
Bromantane (Ladasten) is a small synthetic molecule — not a peptide — that researchers study for its unusual effect of raising the body's own production of dopamine and serotonin by changing how certain genes are expressed, rather than acting like a typical stimulant. It was developed in Russia and is approved there for a specific medical diagnosis, but has no FDA or Health Canada approval. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Bromantane (Ladasten) is a small molecule.
Bromantane (Ladasten) is a lab-made adamantane compound developed in the 1980s at Russia's Zakusov State Institute of Pharmacology. It is an actoprotector, studied for sustaining work capacity. Soviet troops field-tested it in Afghanistan for heat stress and marching fatigue. Unlike most stimulants, it does not act on receptors or block reuptake. Instead it raises gene activity of tyrosine hydroxylase and aromatic L-amino acid decarboxylase (AADC), the slowest steps in making dopamine and serotonin, so cells make more of both. It also strengthens GABA signaling by lowering the GABA transporter, which reports link to calm, not sedation. Russia approved it in 1997 for asthenic disorders (neurasthenia). Reports describe stimulant and calming effects together, with no tolerance, dependence, or withdrawal. A landmark 728-patient clinical trial reported a 76% response rate and 3% side effects.
Key research areas
- Unique dual stimulant-anxiolytic action
- 42% oral bioavailability
- No tolerance or dependence
- 76% clinical response rate in 728-patient trial
- Sustained benefits up to 1 month post-discontinuation
- Enhanced physical performance under stress
- Immunostimulatory effects
Researched dosing
This table shows how researchers have structured study dosing schedules for Bromantane — published research methodology and dose ranges, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Standard cognitive studies | 50mg | Once daily in the morning | Oral |
| Higher-dose studies | 100mg | Once daily or split 50mg twice daily | Oral |
| Starting dose | 25mg | Once daily to assess tolerance | Oral |
| Physical-performance studies | 50-100mg | Once daily, 1-2 hours before activity | Oral |
| Cognitive and mood studies | 50mg | Once daily for 2-4 weeks, then 1-2 weeks off | Oral |
Commonly cycled 4 weeks on, 1+ weeks off.
How it works
At the cell level, Bromantane research looks at how the molecule changes gene expression for two enzymes involved in making dopamine and serotonin — a slower, gene-level mechanism rather than the direct receptor-blocking or reuptake-blocking action of typical stimulants.
Bromantane penetrates neuronal nuclei and promotes demethylation of CpG islands in TH and AADC gene promoter regions, exposing binding sites for transcription factors (CREB, AP2). This induces mRNA synthesis for dopamine and serotonin biosynthetic enzymes — TH mRNA reaches 220% in VTA within 1 hour, with 2-2.5x upregulation in hypothalamus by 1.5-2 hours. Additionally, bromantane reduces GABA transporter (GAT) expression, decreasing GABA reuptake and strengthening GABAergic signaling for anxiolytic effects without sedation. Sustained genomic upregulation over 7-14 days creates stable neurotransmitter enhancement fundamentally different from traditional stimulants.
Molecular data
These figures — molecular weight and chemical structure — are the chemistry fingerprint researchers use to confirm a sample really is Bromantane; note it's a small molecule, not a peptide, so there's no amino-acid sequence to report.
- Weight
- 306.24 Da
- Length
- 0 amino acids
- Type
- N-(4-Bromophenyl)adamantan-2-amine
C16H20BrN (not a peptide — synthetic small molecule)
Pharmacokinetics
This chart shows how a research dose of Bromantane is absorbed and cleared over roughly two days in the published literature — a slower curve than most stimulant-class compounds, consistent with its gene-expression-based mechanism.
- Peak
- 3.375 hr
- Half-life
- 11.21 hrs
- Cleared
- ~0 hrs
Pharmacokinetic Profile Study — Human, 100mg single dose
Research applications
This section lists the body systems and research areas scientists have studied for Bromantane — a summary of what's been investigated in the literature, including its Russian regulatory approval for a specific diagnosis, not medical claims about people.
Cognitive
Sustained dopamine synthesis upregulation provides stable motivational enhancement without the peaks and crashes of reuptake inhibitors. Effects build over 7-14 days and persist after discontinuation. Approved in Russia for asthenic disorders (neurasthenia) — 728-patient trial demonstrated 76% response rate with significant improvements in energy, motivation, and cognitive function. Enhances mental and physical performance under conditions of stress, fatigue, and environmental challenge without cardiovascular strain.
Anxiolytic
Reduces GABA transporter expression, decreasing GABA reuptake and strengthening GABAergic signaling for anxiolytic effects without sedation.
Physical
Actoprotector class — enhances physical endurance and performance under stress conditions including heat stress and fatigue.
Dosage reference
- Doses used in research
- 50 mg
- Frequency in studies
- Once daily, morning preferred
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Acute: mild stimulation 1.5-2h. Days 7-14: full therapeutic effects as TH/AADC gene expression builds. Benefits persist up to 1 month post-discontinuation.
- Storage
- Room temperature, protect from moisture and light
- Cycle length
- 2-4 weeks continuous use recommended
- Break between cycles
- 1-2 weeks break between cycles; effects persist during off-period
Interactions
This list shows which other nootropic and mood-research compounds scientists study alongside Bromantane, and flags pairings that call for extra caution, including certain antidepressant classes.
Reconstitution & storage
Bromantane is studied as an oral compound rather than an injectable, so this section covers measurement and handling notes for research use instead of a mixing procedure.
- For powder: measure precisely with milligram scale due to low dose ranges
- Maintain consistent daily timing for optimal gene expression effects
- Full therapeutic effects develop over 7-14 days of consistent dosing
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, use within Store in cool, dry place protected from light and moisture
Reconstituted: 2-6°C, use within Not applicable — oral solid form
Quality indicators
These are the visual and lab-report checks researchers use to confirm a Bromantane sample is pure and correctly identified, including third-party testing for identity and purity.
White to off-white crystalline powder - High-quality bromantane should be a white to slightly off-white crystalline solid without discoloration or strong odor
Third-party purity testing - Certificate of analysis showing ≥98% purity via HPLC, with identity confirmed by mass spectrometry (MW 306.24)
Proper packaging - Sealed containers with desiccant, batch numbers, and clear labeling. Bromantane is lipophilic and should be protected from moisture.
Research chemical status (US/EU) - Not FDA/EMA approved. Only available through research chemical suppliers or international pharmacies. Quality varies significantly between vendors.
WADA prohibited substance - Banned by WADA since 1997. Athletes subject to anti-doping testing must avoid bromantane. Metabolites detectable up to 14 days.
Yellowing or clumping - Discoloration indicates degradation. Excessive moisture absorption (clumping) compromises the compound.
What to expect
This timeline summarizes what research literature reports at each stage of a study as gene-expression changes build over one to two weeks — research context for comparing studies, not a personal-results promise.
Noticeable improvement in baseline energy, reduced mental fatigue, emerging anxiolytic effects.
Full therapeutic effects as TH/AADC gene expression reaches peak upregulation. Sustained motivation without peaks/crashes.
Maximal benefits — stable mood, physical endurance, cognitive clarity under stress, anxiety reduction.
Safety notes
This section covers handling cautions and regulatory notes for Bromantane in a laboratory setting — including its WADA-prohibited status for athletes — research-use-only scope, not medical safety advice for people.
- Avoid combining with MAOIs — theoretical risk of neurotransmitter accumulation based on mechanism
- Monitor if combining with SSRIs — theoretical concern for metabolic interactions through shared hepatic pathways
- Highly lipophilic — accumulates in adipose tissue, effects and metabolite detection persist longer than half-life suggests
- Not FDA/EMA approved — use under personal discretion with medical supervision
- WADA prohibited substance banned since 1997; metabolites detectable up to 14 days
- Approved in Russia in 1997 for treatment of asthenic disorders (neurasthenia)
Regulatory status
- Not approved by the FDA for any indication.
- Prohibited by the World Anti-Doping Agency (WADA) — added to the Prohibited List in 1997.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
76% response rate on CGI-S and 90.8% improvement on CGI-I. Only 3% experienced side effects with 0.8% discontinuation rate.
Bromantane increases tyrosine hydroxylase (TH) mRNA expression 2-2.5 fold in the rat hypothalamus and striatum, confirming its unique mechanism of enhancing dopamine synthesis at the gene expression level.
42% oral bioavailability, half-life of 11.21 hours, Tmax of 2.75 hours in females and 4 hours in males. Primary metabolite 6β-hydroxybromantane detected in urine up to 2 weeks post-administration.